Ropivacaine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Ropivacaine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Hypotension | 536% |
| Nausea | 283% |
| Vomiting | 117% |
| Bradycardia | 96% |
| Headache | 84% |
| Paresthesia | 82% |
| Fetal bradycardia | 77% |
| Back pain | 75% |
| Pain | 71% |
| Pruritus | 63% |
| Fever | 61% |
| Neonatal jaundice | 49% |
| Postoperative complications | 44% |
| Dizziness | 42% |
| Rigors (chills) | 42% |
| Neonatal complications-nos | 42% |
| Hypoesthesia | 27% |
| Urinary retention | 23% |
| Progression of labor poor/failed | 23% |
| Anxiety | 21% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Ropivacaine hydrochloride injection is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management: epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration
Source: FDA labeling via NIH DailyMed (set 3d465e02…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.